Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells

Jane Yu(Fox Chase Cancer Center), Victoria A. Robb(Fox Chase Cancer Center), Tasha Morrison(Fox Chase Cancer Center), Eric A. Ariazi(Fox Chase Cancer Center), Magdalena Karbowniczek(Fox Chase Cancer Center), Aristotelis Astrinidis(Drexel University), Chunrong Wang(Fox Chase Cancer Center), Lisa Hernandez‐Cuebas(Drexel University), Laura F. Seeholzer(Fox Chase Cancer Center), Émmanuelle Nicolas(Fox Chase Cancer Center), Harvey H. Hensley(Fox Chase Cancer Center), V. Craig Jordan(Fox Chase Cancer Center), Cheryl L. Walker(The University of Texas MD Anderson Cancer Center), Elizabeth P. Henske(Brigham and Women's Hospital)
Proceedings of the National Academy of Sciences
February 7, 2009
Cited by 170Open Access
Full Text

Abstract

Lymphangioleiomyomatosis (LAM) is an often fatal disease primarily affecting young women in which tuberin (TSC2)-null cells metastasize to the lungs. The mechanisms underlying the striking female predominance of LAM are unknown. We report here that 17-beta-estradiol (E(2)) causes a 3- to 5-fold increase in pulmonary metastases in male and female mice, respectively, and a striking increase in circulating tumor cells in mice bearing tuberin-null xenograft tumors. E(2)-induced metastasis is associated with activation of p42/44 MAPK and is completely inhibited by treatment with the MEK1/2 inhibitor, CI-1040. In vitro, E(2) inhibits anoikis of tuberin-null cells. Finally, using a bioluminescence approach, we found that E(2) enhances the survival and lung colonization of intravenously injected tuberin-null cells by 3-fold, which is blocked by treatment with CI-1040. Taken together these results reveal a new model for LAM pathogenesis in which activation of MEK-dependent pathways by E(2) leads to pulmonary metastasis via enhanced survival of detached tuberin-null cells.


Related Papers

No related papers found

Powered by citation graph analysis